|Bid||72.00 x N/A|
|Ask||75.50 x N/A|
|Day's range||73.50 - 74.15|
|52-week range||24.00 - 308.00|
|Beta (5Y monthly)||0.53|
|PE ratio (TTM)||18.52|
|Forward dividend & yield||3.00 (4.04%)|
|Ex-dividend date||04 Mar 2021|
|1y target est||N/A|
Novartis is keeping all options open for the future of its generics division Sandoz, its chairman said in an interview with Swiss TV channel TeleZüri to be broadcast on Tuesday. Asked whether Novartis could merge Sandoz with either Israel's Teva or U.S.-based Viatris or divest it, Joerg Reinhardt said: "All options are open for us." Reinhardt said Novartis's innovative pharma business and the generics business had drifted further apart over the last years so it made sense to examine options now.
Deciphera's (DCPH) sole marketed drug, Qinlock, is approved for treating advanced gastrointestinal stromal tumors. The recent regulatory setback for Qinlock has hurt the stock.
Roche shareholders voted overwhelmingly on Friday to support the $20.7 billion deal to buy Novartis's nearly one third voting stake, the Swiss drugmaker said. Roche held an extraordinary general meeting to settle matters related to its plan to disentangle the two pharma companies, both based in Basel, who had been linked by the investment for two decades. Shareholders approved the audited statutory interim financial statements of the company as of 31 October 2021 with a majority of 100.00%, Roche said.